Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BEIJING HANMI PHARMACEUTICAL CO., LTD. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 1 distinct examiner and are located within 1 distinct art unit. This indicates a high degree of centralization, as all current prosecution matters are being handled by the same individual.
The busiest examiner for this portfolio is DONOGHUE, BRITTNEY ERIN, who is managing 2 pending office actions. Because there is only 1 distinct examiner involved, DONOGHUE, BRITTNEY ERIN is responsible for all of the company's pending workload. This concentration allows the company to develop a consistent strategy across the 2 pending office actions.
The fact that the pending actions are consolidated within 1 distinct art unit suggests that the underlying applications may be closely related. DONOGHUE, BRITTNEY ERIN will have a significant influence on the company's immediate patent outcomes in the Biotechnology & Pharmaceuticals sector. This profile, featuring 1 distinct examiner and 1 distinct art unit, simplifies the management of the current portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 2 | 58.8% | +46.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260682 | ANTI-PD-L1/ANTI-CD47 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF | DONOGHUE, BRITTNEY ERIN | 39d |
| 18260596 | ANTIBODY SPECIFICALLY BINDING TO 4-1BB AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY | DONOGHUE, BRITTNEY ERIN | 41d |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260682 | ANTI-PD-L1/ANTI-CD47 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | DP | Final Rejection | 39d | Pending | Jul 07, 2023 |
| 18260596 | ANTIBODY SPECIFICALLY BINDING TO 4-1BB AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY | DONOGHUE, BRITTNEY ERIN | 1675 | §112Other | Final Rejection | 41d | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial